Breakthrough in Kidney Disease Detection: MICRAL(TM) Urine Dipstick Test

Strategic Insights -

Developed to detect early signs of kidney impairment, the MICRAL(TM) urine dipstick test is poised to revolutionize the diagnostic process for kidney disease. Co-marketed by Boehringer Mannheim Pharmaceuticals Corporation (BMPC) and Boehringer Mannheim Corporation -- Diabetes Care Division (BMC-DC), this innovative product will leverage the strengths of both companies to reach a broader audience. MICRAL(TM) utilizes an immunoassay test strip to identify low levels of albumin in a patient's urine, a clear indicator of renal impairment. This early detection allows physicians to initiate aggressive treatment regimens years before irreversible damage occurs, significantly improving patient outcomes.

Key Takeaways:

  • MICRAL(TM) is the only office-based urine dipstick test capable of detecting low-level kidney impairment, a critical breakthrough in kidney disease diagnosis.
  • The test utilizes an immunoassay test strip to identify low levels of albumin in a patient's urine, a marker of renal impairment.
  • Approximately 3.3 million Americans suffer from kidney problems, with costs estimated at $49 billion annually.
  • Early detection of microalbuminuria (MAU) is crucial for patients at risk of renal disease, allowing for aggressive treatment to prevent irreversible damage.
  • Diagnostic test strips currently in use are less sensitive and non-specific for albumin measurement, highlighting the superiority of MICRAL(TM).
  • The co-promotional agreement between BMPC and BMC-DC aims to promote MICRAL(TM) to physicians in therapeutic areas of cardiovascular, renal, diabetes, and hypertensive medicine.
  • Patients with kidney disease often have comorbidities such as cardiovascular and diabetes conditions, underscoring the importance of comprehensive treatment.
  • BMC-DC brings expertise in diagnostic and diabetes product development, while BMPC enhances the product offering with its marketing and sales strengths in cardiovascular and renal disease.

Statistics:

  • 3.3 million Americans suffer from kidney problems.
  • Annual costs associated with kidney disease are estimated at $49 billion.
  • Diagnostic test strips currently in use are less sensitive, with MICRAL(TM) offering improved measurement of albumin levels.
  • BMPC has launched three products in the last 15 months, including DEMADEX (torsemide), CARDIAC T(TM), and MICRAL(TM).
  • Corange Limited, the parent company of Boehringer Mannheim Corporation and Boehringer Mannheim Pharmaceuticals Corporation, employs 20,000 people worldwide and generates $3.5 billion in annual sales.

Sources:

  • Boehringer Mannheim Pharmaceuticals Corporation press release (HealthWire, July 24, 1995)
  • Boehringer Mannheim Corporation -- Diabetes Care Division press release (HealthWire, July 24, 1995)
  • National Kidney and Urologic Diseases Information Clearinghouse (estimated costs and prevalence of kidney disease)